Skip to main content
OpenTrials
Completed

NCT Number: NCT01557361

Standard Versus Accelerated Initiation of Dialysis in Acute Kidney Injury

The objectives of this trial are to determine whether, in critically ill patients with severe acute kidney injury (AKI), randomization to accelerated initiation of renal replacement therapy (RRT), compared with standard initiation, is:

1. Feasible, in terms of adherence to the protocol (primary outcome), recruitment rates, and achievement of follow-up; and 2. Safe, from the perspective of potential adverse events associated with earlier initiation of RRT

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Alberta Hospital, Edmonton, Alberta, Canada

Loading trial locations.

About this study

Acute kidney injury (AKI) is a common and devastating complication of critical illness. Once AKI is established, treatment is largely supportive and no intervention has been found to restore kidney function or improve overall survival. Renal replacement therapy (RRT), usually in the form of hemodialysis, is frequently needed to manage patients with severe AKI. Such patients have an in-hospital mortality that consistently exceeds 50%. Delay in the initiation of RRT has been implicated as a possible contributor to this poor outcome. A recent meta-analysis suggested that earlier initiation of RRT may improve survival. However, completed trials to date have been small, single centre, limited by study quality, and have shown considerable heterogeneity in terms of definitions used for "early" RRT initiation.

The objectives of this trial are to determine whether, in critically ill patients with severe acute kidney injury (AKI), randomization to accelerated initiation of renal replacement therapy (RRT), compared with standard initiation, is:

  • Feasible, in terms of adherence to the protocol (primary outcome), recruitment rates, and achievement of follow-up; and
  • Safe, from the perspective of potential adverse events associated with the earlier or later initiation of RRT

This pilot trial is intended to guide and inform the design of a phase III multicentre randomized trial of accelerated versus standard initiation of RRT in critically ill patients that will evaluate the impact of the intervention on 90-day all-cause mortality and recovery of kidney function.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(all of these need to be present):

  • Age ≥ 18 years
  • Admission to an intensive care unit
  • Evidence of kidney dysfunction (serum creatinine ≥ 100 µmol/L (women) or

≥ 130 µmol/L (men))

  • Evidence of severe AKI defined by at least 2 of the following 3 criteria:

i-A 2-fold increase in serum creatinine during hospitalization or from a known pre-hospitalization baseline ii-Oliguria as defined by total urine output < 6 mL/kg over the preceding 12 hours iii-Whole blood Neutrophil Gelatinase-Associated Lipocalin (NGAL) ≥ 400ng/mL

  • Likelihood that an absolute indication for RRT will not arise in the subsequent 24 hours based on the most recent bloodwork for the following parameters: i- Serum potassium ≤ 5.5 mmol/L and ii- Serum bicarbonate ≥ 15 mmol/L
  • Central venous pressure ≥ 8 mmHg

Exclusion criteria

(the presence of one of these would disqualify eligibility):

  • Lack of commitment to ongoing life support
  • Presence of a drug overdose that necessitates initiation of RRT
  • Any RRT within the previous 2 months
  • Presence or clinical suspicion of renal obstruction, rapidly progressive glomerulonephritis, vasculitis, or acute interstitial nephritis
  • Advanced chronic kidney disease, defined by an estimated glomerular filtration rate < 30 mL/min/1.73 m2, based on pre-hospitalization blood work
  • Kidney transplant within the past 365 days
  • At the time of screening, doubling of serum creatinine has been present for > 48 hours
  • Clinician(s) caring for patient believe(s) that immediate dialysis is absolutely mandated
  • Clinician(s) caring for patient believe(s) that deferral of dialysis initiation is mandated
  • Patient or substitute decision maker can not provide consent within 12 hours of study eligibility

Treatment and study plan

Accelerated RRT initiation

Other

A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.

Standard RRT initiation

Other

Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:

I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND

II. At least one of the following indications for RRT initiation:

  • Serum potassium ≥6.0 mmol/L, or
  • Serum bicarbonate ≤ 10 mmol/L, or
  • Evidence of severe respiratory failure, based on a PaO2/FiO2 <200 and bilateral infiltrates on the chest x-ray, or
  • By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization

Primary outcomes

  1. Feasibility of protocol adherence

    Time frame: 14 days

    >90% of participants in the accelerated initiation arm start RRT within 12 hours of eligibility AND >90% of participants randomized to the standard initiation arm who ultimately receive RRT, start RRT at least 12 hours following eligibility determination

Secondary outcomes

  1. Feasibility of enrollment

    Time frame: 14 days

    >50% of eligible patients are successfully enrolled in the trial

  2. Feasibility of 90-day follow-up

    Time frame: 90 days

    Vital status and need for RRT at 90 days are successfully captured in >95% of participants

  3. Safety outcomes

    Time frame: 14 days

    Serious adverse effects, with a particular focus on those that are potentially attributable to the study treatment, vascular accesss complications (including hemorrhage, thrombosis and infection) and complications associated with the delivery of RRT (dialysis-associated hypotension, electrolyte abnormalities) will be examined.

Sponsors and collaborators

Lead sponsor

Unity Health Toronto

Other

Collaborators

  • Alere San Diego
  • Canadian Institutes of Health Research (CIHR)

Registry information

Official study title

STandard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI)

Acronym: STARRT-AKI

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Mar 19, 2012
Registry last updated
Sep 12, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.